Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 2:19 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 320 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HSV Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older

NCT01165177
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
16,165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
43
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Nov 2, 2026, 2:19 AM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for the Treatment of Cold Sores

NCT01985321
View directory record Official record
Conditions
Recurrent Herpes Labialis
Interventions
ethanol/glycolic acid solution, Placebo/Ethanol
Drug
Lead sponsor
Topical Remedy
Industry
Eligibility
18 Years to 75 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
8
States / cities
Santa Rosa, California • Pinellas Park, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2015 · Synced Nov 2, 2026, 2:19 AM EST
Not listed Phase 3 Interventional

A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients

NCT00005663
View directory record Official record
Conditions
Herpes Simplex, HIV Infections, Herpes Genitalis
Interventions
Valacyclovir hydrochloride
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
20
States / cities
Berkeley, California • Beverly Hills, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 2, 2026, 2:19 AM EST
Recruiting Phase 2 Interventional

Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease

NCT05907759
View directory record Official record
Conditions
Lymphoma, Primary Effusion
Interventions
Daratumumab SC
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 2, 2026, 2:19 AM EST
Completed Phase 1 Interventional

HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors

NCT02457845
View directory record Official record
Conditions
Supratentorial Neoplasms, Malignant, Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma, PNET, Cerebral Primitive Neuroectodermal Tumor, Embryonal Tumor
Interventions
G207
Biological
Lead sponsor
Gregory K. Friedman, MD
Other
Eligibility
3 Years to 18 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Nov 2, 2026, 2:19 AM EST
Completed Not applicable Interventional

Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster

NCT00006131
View directory record Official record
Conditions
Herpes Zoster, Immunologic Deficiency Syndromes
Interventions
Valacyclovir
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2007 · Synced Nov 2, 2026, 2:19 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Herpesvirus in Idiopathic Pulmonary Fibrosis

NCT00228670
View directory record Official record
Conditions
Lung Diseases, Herpesvirus Infections
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Nov 2, 2026, 2:19 AM EST
Completed Not applicable Interventional

Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer

NCT04540081
View directory record Official record
Conditions
Colon Cancer, Lung Cancer, Tobacco Use Cessation, Obesity, Pneumonia, Bacterial, Shingles, Hepatitis C
Interventions
Epic Healthy Planet Population Health Module
Other
Lead sponsor
University of California, Davis
Other
Eligibility
50 Years to 80 Years
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Nov 2, 2026, 2:19 AM EST
Completed Phase 2 Interventional Results available

Valacyclovir for Mild Cognitive Impairment

NCT04710030
View directory record Official record
Conditions
Mild Cognitive Impairment, Herpes Simplex 1, Herpes Simplex 2
Interventions
Valacyclovir hydrochloride 500mg caplet, Placebo sugar pill caplet
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
50 Years to 95 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Nov 2, 2026, 2:19 AM EST
Completed Not applicable Interventional

Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)

NCT00002026
View directory record Official record
Conditions
Leukoplakia, Hairy, HIV Infections
Interventions
Acyclovir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 2, 2026, 2:19 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age

NCT02075515
View directory record Official record
Conditions
Herpes Zoster, Herpes Zoster Vaccine
Interventions
Herpes Zoster vaccine (GSK 1437173A)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
651 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
3
States / cities
Mesa, Arizona • Wichita, Kansas • Milford, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Nov 2, 2026, 2:19 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier

NCT02581410
View directory record Official record
Conditions
Herpes Zoster
Interventions
GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
65 Years and older
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
32
States / cities
Huntsville, Alabama • Daly City, California • Los Gatos, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Nov 2, 2026, 2:19 AM EST
Completed No phase listed Observational

Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity

NCT02910284
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
Observational
Biological
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
13
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Nov 2, 2026, 2:19 AM EST
Recruiting Phase 2 Interventional

A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

NCT06971614
View directory record Official record
Conditions
Nonmuscle-invasive Bladder Cancer
Interventions
T3011
Biological
Lead sponsor
ImmVira Pharma Co. Ltd
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Queen Creek, Arizona • Los Angeles, California • Orlando, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Nov 2, 2026, 2:19 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age

NCT02979639
View directory record Official record
Conditions
Herpes Zoster
Interventions
GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
404 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
11
States / cities
Oakland, California • Aurora, Colorado • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Nov 2, 2026, 2:19 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older

NCT03439657
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su vaccine GSK1437173A, Prevenar13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
913 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Marlborough, Massachusetts • Salisbury, North Carolina • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Nov 2, 2026, 2:19 AM EST
Completed Phase 4 Interventional Results available

Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab

NCT03798691
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Herpes Zoster
Interventions
Shingrix
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Nov 2, 2026, 2:19 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, PK, and PD Study of a Vaginal Insert Containing TAF and EVG

NCT03762772
View directory record Official record
Conditions
Hiv, HSV
Interventions
TAF/EVG Vaginal Insert
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Nov 2, 2026, 2:19 AM EST
Completed Phase 2 Interventional

A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3

NCT00000712
View directory record Official record
Conditions
HIV Infections
Interventions
Zidovudine, Acyclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
8
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 2, 2026, 2:19 AM EST
Completed Phase 2 Interventional Results available

Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes

NCT02871492
View directory record Official record
Conditions
Herpes Labialis
Interventions
Pritelivir 5% w/w ointment, Pritelivir ointment matching placebo, Zovirax® cream
Drug
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Scottsdale, Arizona • Santa Rosa, California • Pinellas Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Nov 2, 2026, 2:19 AM EST
Completed Phase 3 Interventional

Valaciclovir to Prevent Transmission of Herpes Simplex Virus

NCT00001649
View directory record Official record
Conditions
Herpes Simplex
Interventions
Valaciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 2, 2026, 2:19 AM EST
Completed Not applicable Interventional

Comparison of 2 Vials of Components of a Synthetic Geranium Oil

NCT00611949
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Geranium oil
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 18, 2015 · Synced Nov 2, 2026, 2:19 AM EST
Completed Phase 3 Interventional Results available

Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old

NCT01574612
View directory record Official record
Conditions
Herpes Labialis
Interventions
acyclovir/hydrocortisone cream
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Los Angeles, California • Opa-locka, Florida • West Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Nov 2, 2026, 2:19 AM EST
Not listed Phase 2 Interventional

Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)

NCT00652184
View directory record Official record
Conditions
Herpes Zoster, Postherpetic Neuralgia
Interventions
ARYS-01 (sorivudine) cream 3% or placebo cream, placebo, valaciclovir
Drug
Lead sponsor
aRigen Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Beverly Hills, California • Encino, California • Vista, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2008 · Synced Nov 2, 2026, 2:19 AM EST